Abstract

The glucagon-like peptide-1 (GLP-1) is an endogenous hormone produced by the L cells in the intestine. It is released in response to the intake of food and intestinal dilatation. It stimulates the pancreatic beta-cell to secrete insulin which is dependent upon ingestion of food. GLP-1 acts to slow down gastric motility and suppress appetite through the GLP-1 receptors in the satiety center

Highlights

  • The glucagon-like peptide-1 (GLP-1) is an endogenous hormone produced by the L cells in the intestine

  • GLP-1 acts to slow down gastric motility and suppress appetite through the GLP-1 receptors in the satiety center [1]

  • It is neutralized by the dipeptidyl peptidase-4 (DPP-4) enzyme very quickly

Read more

Summary

Introduction

The glucagon-like peptide-1 (GLP-1) is an endogenous hormone produced by the L cells in the intestine. It is released in response to the intake of food and intestinal dilatation. It stimulates the pancreatic beta-cell to secrete insulin which is dependent upon ingestion of food. GLP-1 acts to slow down gastric motility and suppress appetite through the GLP-1 receptors in the satiety center [1]. It is neutralized by the dipeptidyl peptidase-4 (DPP-4) enzyme very quickly. Administration (FDA) for use in the management of Type 2 diabetes. In combination with other medicinal products for the treatment of diabetes

Mechanism of Action
Clinical Trial Data
Dosing of Oral Semaglutide
Administration of Oral Semaglutide
Who Will Benefit from Oral Semaglutide?
Interactions with Other Medications
Adverse Effects
Conclusion
Findings
Key Learning Points
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call